RedHill Biopharma (RDHL, $0.17) announces positive data of Phase 2 study of RHB-107 for COVID-19
RedHill Biopharma Ltd announced positive observations from a Phase 2 study of RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases.
According to the results, there was a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 treated group versus 15% (3/20) hospitalized on the placebo group. It also revealed an approximate 88% reduction in reported new severe COVID-19 symptoms after treatment was initiated, with just 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled group reporting new severe COVID-19 symptoms. Further investigation suggested a median of 3 days to recovery from severe COVID-19 symptoms with upamostat – much faster compared to eight days with placebo.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RDHL sees its Stochastic Oscillator climbs out of oversold territory
On August 20, 2026, the Stochastic Oscillator for RDHL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 76 instances where the indicator left the oversold zone. In of the 76 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 20, 2026. You may want to consider a long position or call options on RDHL as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RDHL just turned positive on August 13, 2026. Looking at past instances where RDHL's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .
RDHL moved above its 50-day moving average on August 31, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4 3-day Advance, the price is estimated to grow further. Considering data from situations where RDHL advanced for three days, in of 192 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDHL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RDHL broke above its upper Bollinger Band on August 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RDHL entered a downward trend on August 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.240) is normal, around the industry mean (46.950). P/E Ratio (0.086) is within average values for comparable stocks, (93.671). RDHL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.215). RDHL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (9.606) is also within normal values, averaging (176.830).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RDHL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RDHL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in acquisition and development of patented formulations
Industry PharmaceuticalsGeneric
Advertisement